Danish Pharmacovigilance Update, 23 May 2013

In this issue of Danish Pharmacovigilance Update:

• Cases of necrotising fasciitis associated with the use of bevacizumab (Avastin®) (front page)
• Tolvaptan (Samsca®) and potential risk of hepatic injury (p 2)
• Liver fibrosis reported as a potential adverse reaction from the use of methotrexate (p 3)
• The European Medicines Agency (EMA) has started a review of the efficacy and risks of combined use of renin-angiotensin system(RAS)-blocking agents (p 4)